Birdwatch Note
2023-02-02 18:04:26 UTC - NOT_MISLEADING
CDC: "In April 2021, increased cases of myocarditis and pericarditis were reported in the United States after mRNA COVID-19 vaccination (Pfizer-BioNTech and Moderna)." https://www.cdc.gov/vaccines/covid-19/clinical-considerations/myocarditis.html# VAERS received 1991 reports of myocarditis (after receipt of at least 1 dose of mRNA-based COVID-19 vaccine)https://jamanetwork.com/journals/jama/fullarticle/2788346
Written by C378931E048482D2BFDF00DC95644D6377CBCB812C79FF87D77B5E48595B3DA3
Participant Details
Original Tweet
Tweet embedding is no longer reliably available, due to the platform's instability (in terms of both technology and policy). If the Tweet still exists, you can view it here: https://twitter.com/foo_bar/status/1620750400172490753
Please note, though, that you may need to have your own Twitter account to access that page. I am currently exploring options for archiving Tweet data in a post-API context.
All Information
- ID - 1621207934754504706
- noteId - 1621207934754504706
- participantId - C378931E048482D2BFDF00DC95644D6377CBCB812C79FF87D77B5E48595B3DA3
- noteAuthorParticipantId -
- createdAtMillis - 1675361066890
- tweetId - 1620750400172490753
- classification - NOT_MISLEADING
- believable -
- harmful -
- validationDifficulty -
- misleadingOther - 0
- misleadingFactualError - 0
- misleadingManipulatedMedia - 0
- misleadingOutdatedInformation - 0
- misleadingMissingImportantContext - 0
- misleadingUnverifiedClaimAsFact - 0
- misleadingSatire - 0
- notMisleadingOther - 0
- notMisleadingFactuallyCorrect - 0
- notMisleadingOutdatedButNotWhenWritten - 0
- notMisleadingClearlySatire - 0
- notMisleadingPersonalOpinion - 1
- trustworthySources - 1
- summary
- CDC: "In April 2021, increased cases of myocarditis and pericarditis were reported in the United States after mRNA COVID-19 vaccination (Pfizer-BioNTech and Moderna)." https://www.cdc.gov/vaccines/covid-19/clinical-considerations/myocarditis.html# VAERS received 1991 reports of myocarditis (after receipt of at least 1 dose of mRNA-based COVID-19 vaccine)https://jamanetwork.com/journals/jama/fullarticle/2788346
Note Ratings
rated at | rated by | |
2023-02-02 22:31:55 -0600 | 1C88EF08EFE52105DB9D68924F9196E13281BBC7755B7128B294FB964633999A | Rating Details |
2023-02-02 12:32:59 -0600 | 1E63C4F17963B9C5B4489BFDF29FE99946F4AFDBE9F44C5F9A9F6119EB7A78A4 | Rating Details |
2023-02-02 12:46:38 -0600 | 1FDB22A43F03243806F235058C7EEF81B8015C76801FF0195816D9D151CCC7C2 | Rating Details |
2023-02-02 12:32:16 -0600 | 2153359B6D46AFA4B82D4A5535D132AA97A040752ECA68CF72E2C19B23908F05 | Rating Details |
2023-02-02 12:28:23 -0600 | 25BAA22454CDFA1A94AD1D51D4245DE3E6719920C12BDB2F8CDFD35BD6CF6E4C | Rating Details |
2023-02-02 12:49:02 -0600 | 341D0D1F14492D66E6FDE353BE48099C66C772EECB78517BE3D04877355605EF | Rating Details |
2023-02-02 21:28:19 -0600 | 3440E327FFC09396E77E3C806B2CE63500A27905ABDA4DA599C2EFB3935307B4 | Rating Details |
2023-02-02 12:21:30 -0600 | 43004A25B92861EEF3D66B96276AC039C8594CD3B815A5BFA570944FCCFEB21D | Rating Details |
2023-02-03 09:08:26 -0600 | 43E5E7BFBBED8ECC6CCFB5F80F806F8EF3752C9F8F97EB26BCBA7039D8AEA388 | Rating Details |
2023-02-02 12:51:31 -0600 | 464F514091F013106E190C712492FDDD7A2F35D38B0E762F31374CC21B9FD858 | Rating Details |
2023-02-03 08:09:24 -0600 | 479F823F1C14B7E79D4DDECC452FA3B619E14E376DEB831A7DFE7EBACD79C2E2 | Rating Details |
2023-02-02 19:43:19 -0600 | 5A1FBDD73F080A8E8422531A2B7B71060801A5457EB500ED609F226994EE51AD | Rating Details |
2023-02-03 07:23:36 -0600 | 7587F5B33DD8E4C45A2E4C461E5F5B0A54079B0BF91FE7259A82DB5054CF0D6C | Rating Details |
2023-02-02 13:20:50 -0600 | 7BCD718E512E446AEF4EA3476701A4B5789C4CE1DA7ED8BB1EB537225876EA93 | Rating Details |
2023-02-02 12:05:01 -0600 | 803CEE394E0F3E70D4176A8A2D86F197E68B4CD82367AF3F816B5669B0545937 | Rating Details |
2023-02-02 19:41:18 -0600 | 8CAC4F0E509BFA2AC389A16675624816F83E8FA930A8EE68BCA52972B3F41FE9 | Rating Details |
2023-02-03 03:46:25 -0600 | 8E2BA73E12AF4C501F07CFC148A27544B50BF2C5005A428C1CF40AA738BFE37A | Rating Details |
2023-02-02 14:57:03 -0600 | 9545A3E3FC6D4125D44E0A2DB4607FAA05D54E2858EDFFCCBD53A292A79C2967 | Rating Details |
2023-02-02 13:11:27 -0600 | A239AEF1D7F374AA8BED751A725B5647115429299B119475F80B5D381E012CFB | Rating Details |
2023-02-02 12:27:46 -0600 | A631D536112F1A95BC800F9C6242732F5716A8717089F3FCCAF715F75B68A826 | Rating Details |
2023-02-02 19:48:48 -0600 | A82B7826BB7BEF44D4E2949981933C91B27976D6B620BBF6B97C33E8C5EE66E8 | Rating Details |
2023-02-03 08:35:41 -0600 | A9FC5AAA0DB95508452C65451C149C12745C3847F07EC062878E653FB508DAAA | Rating Details |
2023-02-02 12:08:21 -0600 | B0214D11A2C24DE00E6E415EC4ED211F1218A6EA19C2092C000C0CAF1B21FB59 | Rating Details |
2023-02-02 12:30:52 -0600 | C22432C8A2D4D8910FFB425C2FA2BB88E1B7B0105E8BE973EDF7852AEBD31E73 | Rating Details |
2023-02-03 06:58:56 -0600 | C261D94BAE483F2131FACB64C247BAB8FF003F9B21245DB8C9DB1654BD0EED3E | Rating Details |
2023-02-03 05:02:51 -0600 | CA048D6A72AEAD31E09018B6F197C4A1BEBEF805CFE03E8FAA087612D84B9140 | Rating Details |
2023-02-03 00:22:40 -0600 | CE65151EE1AFB9FEB36FA50F86162EB24CE5844A7826EDBECC166CD8F2EC28D9 | Rating Details |
2023-02-03 02:47:10 -0600 | DA84ADC60F3427706D1976474146744FD81A5E48422C01F26B425949D91EEB58 | Rating Details |
2023-02-03 03:46:25 -0600 | Rating Details | |
2023-02-02 12:30:52 -0600 | Rating Details | |
2023-02-02 12:32:59 -0600 | Rating Details | |
2023-02-03 08:09:24 -0600 | Rating Details | |
2023-02-03 00:22:40 -0600 | Rating Details | |
2023-02-02 13:20:50 -0600 | Rating Details | |
2023-02-02 19:48:48 -0600 | Rating Details | |
2023-02-02 12:28:23 -0600 | Rating Details | |
2023-02-03 08:35:41 -0600 | Rating Details | |
2023-02-02 12:32:16 -0600 | Rating Details | |
2023-02-02 19:41:18 -0600 | Rating Details | |
2023-02-02 22:31:55 -0600 | Rating Details | |
2023-02-03 07:23:36 -0600 | Rating Details | |
2023-02-03 06:58:56 -0600 | Rating Details | |
2023-02-03 05:02:51 -0600 | Rating Details | |
2023-02-03 02:47:10 -0600 | Rating Details | |
2023-02-03 09:08:26 -0600 | Rating Details | |
2023-02-02 19:43:19 -0600 | Rating Details | |
2023-02-02 12:05:01 -0600 | Rating Details | |
2023-02-02 12:46:38 -0600 | Rating Details | |
2023-02-02 13:11:27 -0600 | Rating Details | |
2023-02-02 21:28:19 -0600 | Rating Details | |
2023-02-02 12:51:31 -0600 | Rating Details | |
2023-02-02 12:27:46 -0600 | Rating Details | |
2023-02-02 12:49:02 -0600 | Rating Details | |
2023-02-02 14:57:03 -0600 | Rating Details | |
2023-02-02 12:08:21 -0600 | Rating Details | |
2023-02-02 12:21:30 -0600 | Rating Details |